Board of Directors

Learn More

Shane J. Schaffer, PharmD

Chairman, Chief Executive Officer


Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 20-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis and Sanofi (including predecessor companies).


Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products.


Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.

Matthew Brams, MD



Matthew Brams, MD is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors. Dr. Brams is Medical Director and Principal of Bayou City Research, Inc. There, he has been instrumental in gaining FDA approval of over 15 Central Nervous System drugs currently in the marketplace. Dr. Brams is also a Clinical Associate Professor at the Menninger Department of Psychiatry of Baylor College of Medicine and has published over 20 peer-reviewed journal articles.


He has been lead investigator in several pivotal trials involving drugs in ADHD, autism, bipolar disorder and schizophrenia therapeutic areas. He has extensive experience in drug development and execution of Phase I-IV trials and has been involved in over 125 clinical trials in both adult and pediatric populations in all areas of psychiatry. In addition, he has over 25 years of clinical experience managing patients in the field of Adult and Child Psychiatry with particular expertise in ADHD and Autistic Spectrum Disorders (ASD).


He earned his MD from the University of Texas Health Science Center in Houston and completed his residencies at Baylor College of Medicine. He is Board certified in Adult and Child Psychiatry and is a Senior Board Examiner for the American Board of Psychiatry and Neurology.

Patrick Gallagher, MBA, CFA



Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.


Currently a Senior Managing Director at Laidlaw & Co., Mr. Gallagher is an accomplished Capital Markets executive, advisor, and investor with a distinguished record of success in both public and private markets. His day-to-day duties include frequent interaction with institutional investors, C-level corporate executives, KOL’s and industry thought leaders.


Prior to joining Laidlaw & Co. Mr. Gallagher was a founding partner and CEO of BDR Research Group, LLC., a healthcare-focused management consulting and investment research boutique specialized in providing advisory services for healthcare investors and their portfolio companies. He began his career with positions at investment and research firms Kidder Peabody, PaineWebber and New Vernon Associates.


Mr. Gallagher’s leadership and strategy initiatives have included business development, go-to-market planning and execution, and identifying new market opportunities for legacy businesses and product lines at several Biotechnology and Medtech companies, including Cingulate, Athenex (f.k.a. Kinex Pharmaceuticals), BioSig Technologies, Protea Biosciences and Evermore Global Advisors. Mr. Gallagher earned an MBA from Penn State University and a Bachelor of Arts from the University of Vermont.

Laurie Myers, PhD, MBA



Laurie A. Myers, Ph.D is a pharmaceutical executive and entrepreneur whose expertise spans all aspects of branded pharmaceutical life cycle management from drug development and commercialization to strategy and execution of global marketing plans.


Dr. Myers therapeutic expertise includes cardiovascular disease/thrombosis, osteoarthritis and oncology with additional aptitude in infectious disease, neurology/psychiatric disorders and asthma. She has played key role in drug development, marketing and commercialization for leading global pharmaceutical companies, including Novartis, DuPont, Pfizer and Sanofi (including predessor companies) which included leadership positions in both R&D and marketing. She has been named to the Top 100 Brand Champions by Pharma Voice.


Dr. Myers is a founding member of the Cingulate Therapeutics Board of Directors and has contributed to two investor organizations; Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures and was commercial advisor to another start-up, EpiGen Pharma.


Dr. Myers earned her PhD in Toxicology from Rutgers Medical School/Rutgers School of Pharmacy in New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia, PA. She has served as Adjunct Professor at The College of New Jersey School of Business.

Arthur B. Straughn, PharmD



Dr. Straughn is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.


During his 40 years as Professor and Director of the Drug Research Laboratory in the Department of Pharmaceutical Sciences at the College of Pharmacy, University of Tennessee, Dr. Straughn was responsible for the design and conduct of over 200 clinical trials to evaluate drug formulations for effectiveness and safety.


His career has provided him ample opportunity to consult with numerous pharmaceutical companies in helping them develop innovative drug formulations with unique drug delivery properties. More recently he has served as an expert witness in litigations involving patent issues relative to new drug formulations.


Dr. Straughn received his BS in Pharmacy from the University of North Carolina and his Doctor of Pharmacy from the University of Tennessee.